Description
Plinest Eye – is a specialized injectable treatment designed to target the delicate skin around the eyes. Formulated with polynucleotides, this advanced solution revitalizes the under-eye area, improving hydration, elasticity, and overall texture. It works by stimulating cell regeneration, enhancing collagen production, and promoting microcirculation, helping to reduce the appearance of dark circles, fine lines, and puffiness.
Plinest Eye is the ideal solution for those looking to rejuvenate the eye area and reduce fine lines for a brighter, more youthful appearance. Suitable for all skin types, it offers a gentle, non-surgical approach to eye contour revitalization.
Composition of Plinest Eye
- 15 mg of polynucleotides (7,5mg/ml)
Indications:
- Rejuvenation of the eye area.
- Reduction of dark circles (pigment or vascular)
- Treatment of bags under the eyes.
- Smoothing of fine wrinkles.
- Moisturizing and revitalizing the delicate skin around the eyes
- Improves skin elasticity.
- Skin revitalization.
Benefits of Plinest Eye
- Improving the structure of the skin around the eyes, reducing wrinkles and adding elasticity.
- Protecting cell DNA from damage and active regeneration.
- Preventing and combating signs of aging in the periorbital area.
- Maintaining a youthful and fresh look.
Areas:
- Eye contour
- Eyelids
Format:
1 syringe of 2 ml
Manufacturer:
- Format: 1 syringe of 2 ml
- Application by a certified professional
Used for:
- Rejuvenation of the eye area.
- Reduction of dark circles (pigment or vascular)
- Treatment of bags under the eyes.
- Smoothing of fine wrinkles.
- Moisturizing and revitalizing the delicate skin around the eyes
- Improves skin elasticity.
- Skin revitalization.
Plinest Eye 1 x 2 ml

Discover 5 reasons to order Plinest Eye. This advanced treatment restores skin firmness, reduces fine lines, and hydrates the delicate eye area for a youthful, refreshed look.
Product Brand: MASTELLI
Product Currency: $
Product Price: 45
Product In-Stock: InStock
5
Reviews
There are no reviews yet.